Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Marie Skłodowska-Curie Action · Running

ADHESYS A Breakthrough Mucoadhesive 3D-Printed Delivery System to Treat Oral Mucositis in Cancer Patients

Coordinator
Universitetet I Oslo, Norway
Runs
1 August 2026 to 31 July 2028
Status
Running
EU funding
€252k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101271061

What the project is doing

In the project's own words, from its summary on CORDIS.

Oral mucositis (OM) is one of the most frequent and debilitating side effects of cancer therapy, characterised by persistent inflammation, painful intraoral lesions and ulcers, impaired nutrition, and increased infection risk. It affects about 50% of patients receiving chemotherapy and up to 90% of those undergoing radiotherapy, significantly compromising their daily lives and contributing to substantial healthcare costs, often exceeding several thousand euros per patient.

Despite its prevalence, no effective treatments currently exist. Conventional drug delivery systems are not able to treat cancer therapy-induced OM since they are not multi-targeted and their retention time in the oral cavity is too short. Supported by the Marie Skłodowska-Curie Actions programme, ADHESYS redefines an innovative therapeutic option for supportive cancer care. The project aims to produce and characterize a nature-based mucoadhesive film that provides targeted and long-lasting pro-healing effects, thus moving beyond mere symptomatic relief.

The film will incorporate nanoencapsulated bioactive polyphenols extracted from Aronia melanocarpa pomace, a sustainable food by-product of the juice industry. Engineered using only natural and biocompatible materials, the film will be fabricated via semisolid extrusion 3D-printing, offering superior reproducibility, commercial scalability, and a patient-tailored design compared to conventional film manufacturing methods.

By co-delivering multiple bioactive polyphenols with synergistic antioxidant, anti-inflammatory, and wound healing effects directly to the affected area, this unique precision-medicine tool will promote OM healing, thus enhancing the oral health and quality of life of millions of cancer patients worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I OsloOsloNorwayCoordinator
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI